ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comprehensive Genomic Profiling Beyond Driver Testing in Non-Squamous Non-Small Cell Lung Cancer With Known Drivers.Cancer science · 2026Article
- Advances in therapeutic approaches to gastric cancer.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
purposeGastrointestinal tumors, including esophageal and gastric/gastroesophageal junction adenocarcinoma (GEA), have a high mortality rate and present significant treatment challenges. Telisotuzumab adizutecan (Temab-A, ABBV-400), a novel antibody-drug conjugate targeting the c-Met protein (also known as MET protein), has shown encouraging results in patients with advanced GEA. PATIENTS AND
methodsThis phase I, open-label, multicenter study assessed the safety, efficacy, and pharmacokinetics (PK) of Temab-A monotherapy (3 mg/kg every 3 weeks intravenously) in patients with advanced GEA. Patients ≥18 years of age with advanced/metastatic GEA who had received 1 to 2 prior systemic therapies were included. The primary objectives were the evaluation of safety, PK, and efficacy; efficacy endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). c-Met expression and MET amplification were retrospectively assessed.
resultsForty-two patients with advanced GEA were enrolled; the median age was 60 years. The median follow-up duration was 12.6 months. All patients had one or more treatment-emergent adverse events (TEAE), with 88% experiencing grade ≥3 TEAEs. The most common hematologic TEAEs were anemia (67%), nausea (52%), and decreased appetite (36%). The ORR was 29%, the clinical benefit rate was 71%, and the median DOR was 4.2 months. The median PFS was 4 months, and the median OS was 5.8 months. Exploratory biomarker analyses showed ORR enrichment in patients with higher c-Met protein expression and MET focal amplification.
conclusionsTemab-A monotherapy demonstrated antitumor activity and a manageable safety profile in patients with advanced GEA. The findings support further clinical development of Temab-A, particularly in combination with other agents to improve outcomes for patients with 2L+ GEA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.